February 1, 2022 – BD announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring research for blood diseases.
The acquisition of Cytognos accelerates BD’s strategy to support chronic disease management by expanding its portfolio of blood cancer diagnostics, immune assessment tests and informatics to address patient, clinician and care provider needs to better understand the immune system, immune response and MRD. By monitoring for MRD, lab managers and physicians can detect low levels of cancer cells following treatment that alerts them if the disease is still present or if there is a signal of recurrence. This is a key element of the patient care continuum that helps clinicians and physicians recognize when cancer recurs and aids in the timely treatment of patients.
Cytognos’ key products increase BD’s comprehensive portfolio of diagnostic and research solutions for certain types of cancers that use flow cytometry as the primary means of discovery, diagnosis and understanding, including lymphoma, leukemia and multiple myeloma. Cytognos IVD products are CE marked and available only in Europe and other countries where regulatory approval of the products has been obtained. They are not available for sale in the U.S. In addition, Cytognos provides several research assays for multiple myeloma MRD and immune monitoring, which expands BD’s portfolio in this space. Cytognos’ approximately 80 employees will join BD as a result of the acquisition.
Cytognos also brings sophisticated informatics solutions that will further BD’s leadership in the growing area of immunology and enable the company to expand its flow informatics offerings. In a world of limited resources and increasing data and settings, Cytognos technology offers a powerful, intuitive way that provides a better understanding of patient data.